Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection[1].
Molecular Weight:
(145.1 kDa)
Purity:
98.66
CAS Number:
[2135632-29-8]
Target:
Filovirus
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted